Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Harnessing data science to advance radiation oncology

    Research output: Contribution to journalReviewResearchpeer-review

  2. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Proposal of a new grading system for meningioma resection: the Copenhagen Protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aimed to investigate whether AGT promoter methylation in tumor tissue predicts response to bevacizumab combination therapy in patients with recurrent glioblastoma. The study included 159 patients with recurrent glioblastoma, treated with bevacizumab combination treatment (training cohort, n = 77; validation cohort, n = 82). All patients could be evaluated for treatment response and biomarkers. DNA methylation of 4 CpG sites in the AGT promoter was measured using pyrosequencing. A model for nonresponse was established using logistic regression analysis. In the training cohort, lower methylation of each of the four CpG sites in the AGT promoter was significantly associated with nonresponse (all P ' 0.05). Moreover, the mean methylation level of all four CpG sites was associated with an increased likelihood of not achieving response to bevacizumab combination therapy (twofold decrease: odds ratio = 3.01; 95% confidence interval: 1.41–6.44; P = 0.004). We developed a model for nonresponse in the training cohort, where a threshold of mean AGT promoter methylation levels was set to below 12%. The model could predict bevacizumab nonresponse with 96% specificity. Importantly, this predictor was also significantly associated with nonresponse in the validation cohort (P = 0.037). Taken together, our findings suggest that low AGT promoter methylation in tumor tissue predicts nonresponse to bevacizumab combination treatment in patients with recurrent glioblastoma. We have, thus, established and successfully validated a predictor for nonresponse that can be used to identify patients who will not benefit from bevacizumab combination therapy.

Original languageEnglish
JournalMolecular Oncology
Volume14
Issue number5
Pages (from-to)964-973
Number of pages10
ISSN1574-7891
DOIs
Publication statusPublished - May 2020

Bibliographical note

© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

    Research areas

  • bevacizumab, DNA methylation, glioblastoma, local renin–angiotensin system, predictive biomarker

ID: 59545203